---
figid: PMC9500901__pharmaceuticals-15-01147-g001
pmcid: PMC9500901
image_filename: pharmaceuticals-15-01147-g001.jpg
figure_link: /pmc/articles/PMC9500901/figure/pharmaceuticals-15-01147-f001/
number: Figure 1
figure_title: ''
caption: 'Leukotriene pathway and its inhibitors: Membrane phospholipids hydrolyzed
  by phospholipase A to arachidonic acid (AA), which, by the action of 5-lipoxygenase
  (5-LO), convert to leukotriene A4 (LTA4). Further, LTA4 is converted to LTB4 by
  the action of LTA4 hydrolase and to cysteinleukotriene (CysLT) by the action of
  LTC4 synthase. CysLTs act on CysLT receptors (CysLT1R and CysLT2R).'
article_title: 'Montelukast and Acute Coronary Syndrome: The Endowed Drug.'
citation: Basil Mohammed Alomair, et al. Pharmaceuticals (Basel). 2022 Sep;15(9):1147.
year: '2022'

doi: 10.3390/ph15091147
journal_title: Pharmaceuticals
journal_nlm_ta: Pharmaceuticals (Basel)
publisher_name: MDPI

keywords:
- acute coronary syndrome
- leukotriene
- montelukast
- antileukotrienes therapy

---
